The U.S. Food and Drug Administration (FDA) approved the first generic version of dapagliflozin on April 6, 2026. This approval, granted to MACLEODS PHARMS LTD., marks a significant step in expanding access to this medication.
Background
Dapagliflozin is a widely recognized medication, available under brand names such as Farxiga and in combination formulations like Xigduo XR (with metformin hydrochloride). The approval of an Abbreviated New Drug Application (ANDA) signifies that the generic drug is bioequivalent to its brand-name counterpart, meaning it works in the same way and provides the same clinical benefit. Generic drugs become eligible for approval once the patent and exclusivity protections for the original brand-name drug have expired. This process is crucial for increasing access to essential medications by fostering competition among manufacturers.
What this means
The FDA's approval of MACLEODS PHARMS LTD.'s generic version of dapagliflozin is a significant development for patients and healthcare providers. Generic medications offer a cost-effective alternative to brand-name drugs, which can lead to substantial savings for individuals and the healthcare system. By making a generic option available, this approval helps to improve patient access to dapagliflozin, ensuring that more people can benefit from this important treatment. Generic drugs undergo rigorous review by the FDA to ensure they meet the same high standards for quality, strength, purity, and stability as their brand-name equivalents.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Abbreviated New Drug Application (ANDA) 211506 was posted on April 6, 2026, on accessdata.fda.gov.